Engineered Ig Lambda Locus for Diverse Human Antibody Repertoires
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current systems for producing human monoclonal antibodies in transgenic animals do not maximize human antibody repertoires, limiting the development of effective therapeutics.
Innovation Solution
Engineering non-human animals with an immunoglobulin lambda light chain locus that includes operably linked human Vλ, Jλ, and Cλ gene segments, along with human immunoglobulin enhancers, to enhance the diversity and performance of human antibody repertoires.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If transgenic animals are engineered with genetic material encoding human antibodies, then human antibody production capability is improved, but the diversity and performance of human antibody repertoires are not maximized
Solution Approach 1:
The patent segments the human immunoglobulin lambda light chain locus into distinct functional components (Vλ gene segments, Jλ gene segments, Cλ region genes, and enhancer elements) and inserts them into the rodent genome in an organized, operably linked arrangement. This segmentation allows systematic construction of the engineered locus while maintaining proper gene structure and regulation, thereby increasing antibody repertoire diversity without overwhelming complexity.
Solution Approach 2:
The engineered immunoglobulin locus is designed to serve multiple functions simultaneously: it enables production of human lambda light chains, maintains proper B cell development through functional enhancer elements, and allows diverse antibody repertoire generation through multiple Vλ and Jλ gene segments. This multi-functionality resolves the contradiction by making a single engineered locus perform several critical roles.
2Quantity of substance
If the immunoglobulin locus includes multiple human Vλ, Jλ, and Cλ gene segments, then antibody repertoire diversity is improved, but the genetic engineering complexity increases
Solution Approach 1:
The patent nests multiple human gene segments (Vλ, Jλ, Cλ) within the engineered immunoglobulin locus in a hierarchical arrangement that mimics natural gene organization. The Vλ segments are positioned upstream, followed by Jλ segments, and Cλ regions downstream, all nested within rodent genomic context elements including enhancers and regulatory sequences. This nested structure allows incorporation of numerous gene segments while maintaining manageable genetic architecture.
Solution Approach 2:
The patent performs preliminary design and organization of the human immunoglobulin lambda light chain locus components before insertion into the rodent genome. The Vλ, Jλ, and Cλ segments are pre-assembled in their correct operable linkage with appropriate enhancer elements, ensuring proper spatial and functional arrangement. This preliminary action reduces the complexity of subsequent integration and ensures immediate functionality upon insertion.
3Reliability
If human immunoglobulin enhancers are included in the engineered locus, then antibody expression performance is improved, but the genetic engineering complexity increases
Solution Approach 1:
The patent introduces human immunoglobulin enhancer elements as intermediary regulatory components that mediate between the inserted human Vλ-Jλ-Cλ gene segments and the rodent genomic environment. These enhancers serve as adaptive intermediaries that ensure proper transcriptional activation, chromatin accessibility, and B cell development signals, thereby improving antibody expression performance while simplifying the integration of human genes into the rodent system.
Data Source
AI summary
Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non-human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). Non-human animals described herein express antibodies that contain human Igλ light chains, in whole or in part. In particular, non-human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Igλ light chains, in whole or in part, that are encoded by human Ig light chain-encoding sequences inserted into an endogenous Igλ light chain locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided.